Skip to main content
Premium Trial:

Request an Annual Quote

Lumivi Diagnostics SARS-CoV-2 Rapid IgG Test Receives Health Canada Authorization

NEW YORK – Lumivi Diagnostics announced recently that its SARS-CoV-2 IgG Rapid Test has received Health Canada authorization.

The company, a Canadian joint venture formed in 2020 between Immune Response Diagnostics, an affiliate of International Point of Care, and Suncor Energy, said in a statement that its single-use test returns results within 15 minutes and is intended to be used by laboratory personnel and other healthcare professionals. Sensitivity and specificity are both greater than 98 percent, it added.

The test detects immunoglobulin G antibodies in plasma and serum and doesn't require an analyzer. It can assess if someone has had prior exposure to COVID-19. The kit is available for purchase now with delivery expected in mid-July.